Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders
US-2024041900-A1 · Feb 8, 2024 · US
Activated nitric oxide donors and methods of making and using thereof
US9005656B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9005656-B2 |
| Application number | US-92122709-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 5, 2009 |
| Priority date | Mar 7, 2008 |
| Publication date | Apr 14, 2015 |
| Grant date | Apr 14, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are compositions useful in anticancer treatment and prevention. The compositions are composed of (a) an O 2 -aryl substituted diazeniumdiolate and (b) an amphiphile, wherein the amount of amphiphile is sufficient to produce a liposome or micelle. The compositions described herein provide numerous advantages such as increased solubility and stability of the O 2 -aryl substituted diazeniumdiolate in vivo. The compositions also do not induce hypotension. Methods for using the compositions in anticancer treatment and prevention are also described herein.
First claim
Opening claim text (preview).
What is claimed: 1. A composition produced by the process comprising admixing (a) O 2 -(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K) or the pharmaceutically acceptable salt or ester thereof; and (b) a poloxamer having the formula HO(C 2 H 4 O) b (C 3 H 6 O) a (C 2 H 4 O) b H wherein a is from 50 to 80 and b is from 10 to 25, wherein the amount of poloxamer is sufficient to produce a micelle. 2. A pharmaceut…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K31/655Primary
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9005656B2 cover?
- Described herein are compositions useful in anticancer treatment and prevention. The compositions are composed of (a) an O 2 -aryl substituted diazeniumdiolate and (b) an amphiphile, wherein the amount of amphiphile is sufficient to produce a liposome or micelle. The compositions described herein provide numerous advantages such as increased solubility and stability of the O 2 -aryl substituted…
- Who is the assignee on this patent?
- Shami Paul J, Kosak Ken M, Univ Utah Res Found
- What technology area does this patent fall under?
- Primary CPC classification A61K31/655. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).